Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 52Carcinoma, Renal Cell 47Neoplasm Metastasis 24Neoplasms 18Kidney Neoplasms 18Neuroendocrine Tumors 17Carcinoma, Non-Small-Cell Lung 13Tuberous Sclerosis 12Stomach Neoplasms 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Recurrence 10Prostatic Neoplasms 10Lymphoma 10Hodgkin Disease 10Glioblastoma 10Colorectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Brain Neoplasms 9Lymphoma, Follicular 8Lung Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma 8Waldenstrom Macroglobulinemia 7Triple Negative Breast Neoplasms 7Sarcoma 7Multiple Myeloma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Central Nervous System Neoplasms 7

Interventions

Omeprazole 2Lansoprazole 2Esomeprazole 2pazopanib 1cixutumumab 1Temozolomide 1Streptozocin 1Salts 1Pantoprazole 1Octreotide 1Interferons 1Fluorouracil 1Everolimus 1Doxorubicin 1Dexlansoprazole 1Clopidogrel 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Zollinger-Ellison Syndrome × Everolimus × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡